Norway pharmacy online: Kjøp av viagra uten resept i Norge på nett.

Jeg har selv prøvd dette kamagra Det er billig og fungerer egentlig, jeg likte det) kjøp cialis Ikke prøvd, men du kan eksperimentere med... Hvordan føler du deg, følsomhet etter konsumere piller?.

Cv_feki

Department of Obstetrics and Gynecology Hôpital Cantonal Fribourgeois Case postale 1708 Fribourg Home: 4, route de Genolier 1266 Duillier Languages written and spoken: French, Italian, German, English, and Arabic Head of the Department of obstetrics and gynecology. Hopital cantonal fribourgeois. Switzerland. Director of the Stem Cell Research Laboratory. Geneva University Hospital. Switzerland M.SC in physics. Canada MD in medicine with honors. Tunis Faculty of Medicine. Tunisia Title: The importance of thoracic surgery in multi-drug resistant tuberculosis Swiss equivalence of the MD degree Diploma of Specialization in Reproductive Medicine and Reproductive Biology. Faculty of Diploma of Specialization in Medical Biology. Faculty of Sciences. Geneva University Certificate in Entrepreneurship. Geneva University & EPFL-Lausanne MD in medicine with the price of the best medical thesis. Faculty of medicine. Geneva University Title: The role of BARD1 in tumor suppression in an animal cancer model. Thesis director: professor Karl-Heinz Krause PhD in Biology. Faculty of Sciences, Geneva University Molecular characterization of the tumor suppressor gene BARD1 in development and tumor suppression. Thesis director: professors Karl-Heinz Krause and Ueli Schibler FMH in obstetrics and gynecology FMH in operative obstetrics and gynecology FMH in reproductive medicine and in gynecologic endocrinology Chef de clinique. Reproductive medicine and endocrinology unit. Service of gynecology. Department of obstetrics and gynecology. Geneva University Hospitals. Switzerland Fellowship and consultant in Reproductive medicine unit. Service of gynecology. Catholic University of Louvain. Brussels. Belgium Chef de clinique. Reproductive medicine and endocrinology unit. Service of gynecology. Department of obstetrics and gynecology. Geneva University Hospitals. Switzerland Resident in the service of gynecology. Department of obstetrics and gynecology. Geneva University Hospitals. Switzerland Resident in the service of obstetrics. Department of obstetrics and gynecology. Geneva University Hospitals. Switzerland Resident, Biology of Aging Laboratory: Geriatric department. Geneva University Hospitals. Switzerland Resident, Department of obstetrics and gynecology. Geneva University Hospitals. Switzerland Resident, Department of obstetrics and gynecology, Tunisia Resident, Department of thoracic surgery. Tunisia Resident, Department of pediatrics. Tunisia Resident, Department Resuscitation. Tunisia Resident, Department of psychiatry. Tunisia Resident, Department of surgical oncology. Tunisia Novel approaches for the derivation of human embryonic stem cells: animal-free conditions, maintenance of pluripotency, and clonal expansion. Clinical grade iPS generation: genetic stability, pluripotency and self-renew analysis Pre-graduate teaching (APP). 32 hours per year. Geneva Faculty of Medicine. Switzerland Pre-graduate teaching (APP). 32 hours per year. Geneva Faculty of Medicine. Switzerland Graduate teaching (AMC). 24 hours per year. Geneva Faculty of Medicine. Switzerland Graduate teaching (AMC). 24 hours per year. Geneva Faculty of Medicine. Switzerland Graduate teaching (AMC). 24 hours per year. Geneva Faculty of Medicine. Switzerland The American Association for Cancer Research Pezcoller Foundation Scholar in Training Award Geneva Faculty of Medicine price for the best thesis Bayer-Schering award of the Swiss Society of Obstetrics and Gynecology Member of the American Association for Cancer Research (AACR) Member of the American Society of Clinical Oncology (ASCO) Member of the Swiss MD-PhD Association (SMPA) Board Executive Member of the European Society of Human Reproduction and Embryology (ESHRE) SIG deputy member of ESHRE Member of the International Society of Stem Cell Research (ISSCR) President of the Association des Médecins Assistants en Recherche (AMIR) Ad hoc reviewer for research articles in New England Journal of Medicine, International Journal of Biochemistry and Cell Biology, Neuro-urology and Urodynamics journal, Pathobiology journal, Stem Cells, Stem Cell & Development, Human Reproduction, e-Cells and Materials Journal, Stem Cell Research, Journal of Cellular Biochemistry and Biotechnology Progress, PLoS One. SCORE (Swiss Clinician Opting for Research) of the Swiss National Foundation grant: SNF: 3232B0-111339/1: 368’784. - Sfr SNF: 3200B0-111340/1: 400’000. – Sfr January 2006- December 2006: Research fund of the department of obstetrics and gynecology, Geneva University Hospital: 8’000. – Sfr January 2007- December 2008: Roche Research Foundation Subside: 32’750. - Sfr Ernst & Lucie Schmidheiny Foundation Grant: 20’000. - Sfr Bayer-Schering award of the Swiss Society of Obstetrics and Gynecology: 10’000. – Sfr January 2008- December 2009: Grant from the International Society of IVF & IVM: 20’000 $ April 2010- March 2012: Grant from Genico SA: 276’000. – Sfr November 2011-October 2012 Grant from Gertrude Von Meissner Foundation: 50’000. –Sfr November 2011-October 2012 Grant from Dr Henri Dubois-Ferrière Dinu Lipatti Foundation: 80’000. –Sfr Grant from the Ernest Boninchi Foundation: 72’000. –Sfr EOS/SPIE European Biomedical Optics Weeks – EbiOS. 2000 Meeting of the International Society of Fertility and Sterility. Edinburgh. 2000 Cancer detection and prevention Meeting, Geneva. 2001 92nd Annual meeting of the AACR, New Orleans. 2001. XIXe Congrès de la Société d’Andrologie de Langue Française. SALF 2002, 12-14 December, Geneva Cancer, Apoptosis and Aging workshop. Geneva. 2002. 6th interactive day between Geneva and Lausanne medicine Faculties. Changin. 2002. 3rd Joint meeting of the British Andrology Society, the British Fertility Society and the Society for Reproduction and fertility. Aberdeen 2003 Anti-Aging Medicine World Congress 2007, Monaco March 22-23-24 International Initiative for Stem Cell Research 2007, Bar Harbor October 18-19 Annual meeting of the Mediterranean Society of Reproductive Medicine 2008, Tunisia May 15-18 Annual meeting of the Middle East Fertility Society 2008, Tunisia October 15-18 15th World congress on IVF and IVM. Geneva, Switzerland, 19-22 April 2009. 6th International Stem Cell School in Regenerative Medicine 2009. Odense, Denmark, 14-16 June, 2009. ESHRE annual meeting. Amsterdam, 28-1 july 2009. ESHRE annual meeting. Rome, 27-30 June 2010. 2010 Advanced Course of Mastology. Mastology Association of the Northern and Southern Mediterranean. Geneva 2010. Switzerland The 20th STGO, 4th FGOM, and the 11th FEMGO joint meeting. 7 to 9th October 2010. Tunis. Tunisia 29ème Congrès National de la SRMGO. 4 - 5 Février 2011 Hôtel Sheraton. Casablanca. Marocco The Gyn2011 congress. 9-11th June 2011. Monaco Third Congress of the Society of Reproductive Medicine. Antalya, October 5th and 9th, 2011 Cell Symposia. Stem Cell Programming & Reprogramming. Lisbon, Portugal. December 8–10 2011. Original articles published or accepted in peer reviewed journals: Stefano Camnasio, Alessia Delli Carri, Angelo Lombardo, Iwona Grad, Caterina Mariotti, Alessia Castucci, Björn Rozelle, Pietro Lo Riso, Valentina Castiglioni, Chiara Zuccato, Christelle Rochon, Cinzia Gellera, Marisa Jaconi, Austin Smith, Outi Hovatta, Luigi Naldini, Stefano Di Donato, Anis Feki, Elena Cattaneo. Induced pluripotent stem cells from patients with homozygous and heterozygous Huntington’s disease exhibit enhanced lysosomal activity. Accepted in Neurobiology of Disease . (IF: 5.121) The International Stem Cell Initiative, Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC, Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E, Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De Sousa PA, Denning C, Downie J, Dvorak P, Montgomery KD, Feki A, Ford A, Fox V, Fraga AM, Frumkin T, Ge L, Gokhale PJ, Golan-Lev T, Gourabi H, Gropp M, Guangxiu L, Hampl A, Harron K, Healy L, Herath W, Holm F, Hovatta O, Hyllner J, Inamdar MS, Irwanto AK, Ishii T, Jaconi M, Jin Y, Kimber S, Kiselev S, Knowles BB, Kopper O, Kukharenko V, Kuliev A, Lagarkova MA, Laird PW, Lako M, Laslett AL, Lavon N, Lee DR, Lee JE, Li C, Lim LS, Ludwig TE, Ma Y, Maltby E, Mateizel I, Mayshar Y, Mileikovsky M, Minger SL, Miyazaki T, Moon SY, Moore H, Mummery C, Nagy A, Nakatsuji N, Narwani K, Oh SK, Oh SK, Olson C, Otonkoski T, Pan F, Park IH, Pells S, Pera MF, Pereira LV, Qi O, Raj GS, Reubinoff B, Robins A, Robson P, Rossant J, Salekdeh GH, Schulz TC, Sermon K, Mohamed JS, Shen H, Sherrer E, Sidhu K, Sivarajah S, Skottman H, Spits C, Stacey GN, Strehl R, Strelchenko N, Suemori H, Sun B, Suuronen R, Takahashi K, Tuuri T, Venu P, Verlinsky Y, Oostwaard DW, Weisenberger DJ, Wu Y, Yamanaka S, Young L, Zhou Q. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011 Nov 27. doi: 10.1038/nbt.2051. (IF: 31.1) Grad I, Hibaoui Y, Jaconi M, Chicha L, Bergström-Tengzelius R, Sailani MR, Pelte MF, Dahoun S, Mitsiadis TA, Töhönen V, Bouillaguet S, Antonarakis SE, Zucchelli M, Hovatta O, Feki A. Nanog Priming Before Full Reprogramming May Generate Germ Cell Tumors. Accepted in eCM journal. (IF: 9.650) Fernández M, Pirondi S, Chen BL, Del Vecchio G, Alessandri M, Farnedi A, Pession A, Feki A, Jaconi ME, Calzà L. Isolation of rat embryonic stem-like cells: A tool for stem cell research and drug discovery. Dev Dyn. 2011 Nov;240(11):2482-94. doi: 10.1002/dvdy.22761. (IF: 2.864) Laurie Chicha, Anis Feki, Outi Hovatta, Olivier Irion, Marisa Jaconi. Human Embryonic and Induced Pluripotent Stem Cells Differentiated in Fully Defined Medium Generate Hematopoietic CD34+ and CD34- Progenitors with Distinct Characteristics. PLoS one. 2011 (IF: 4.351) De Rosa A, Tirino V, Paino F, Tartaglione A, Mitsiadis T, Feki A, d'Aquino R, Laino L, Colacurci N, Papaccio G. Amniotic fluid-derived MSCs lead to bone differentiation when co-cultured with dental pulp stem cells. Tissue Eng Part A. 2010 Nov 22. (IF: 4.582) Hovatta O, Jaconi M, Töhönen V, Béna F, Gimelli S, Bosman A, Holm F, Wyder S, Zdobnov EM, Irion O, Andrews PW, Antonarakis SE, Zucchelli M, Kere J, Feki A. A teratocarcinoma-like human embryonic stem cell (hESC) line and four hESC lines reveal potentially oncogenic genomic changes. PLoS one. 2010 Apr 23;5(4):e10263. (IF: 4.351) Holm F, Ström S, Inzunza J, Baker D, Strömberg AM, Rozell B, Feki A, Bergström R, Hovatta O. An effective serum- and xeno-free chemically defined freezing procedure for human embryonic and induced pluripotent stem cells. Hum Reprod. 2010 Mar 5. [Epub ahead of print]. (IF: 3.859) Unger C, Gao S, Cohen M, Jaconi M, Bergstrom R, Holm F, Galan A, Sanchez E, Irion O, Dubuisson JB, Giry-Laterriere M, Salmon P, Simon C, Hovatta O, Feki A. Immortalized human feeder cells which maintain human embryonic stem cell pluripotency and the generation of induced pluripotent stem cells. Human reproduction. 2009 Jul 3. [Epub ahead of print]. (IF: 3.859) Suter DM, Preynat-Seauve O, Tirefort D, Feki A, Krause KH. Phenazopyridine induces and synchronizes neuronal differentiation of embryonic stem cells. J Cell Mol Med. 2009 Jan 16. (IF: 6.807) Preynat-Seauve O, Suter DM, Tirefort D, Turchi L, Virolle T, Chneiweiss H, Foti M, Lobrinus JA, Stoppini L, Feki A, Dubois-Dauphin M, Krause KH. Development of brain-like human tissue upon differentiation of embryonic Stem cells in three dimensional culture. Stem Cells. 2008 Dec 11. (IF: 7.741) Feki A, Bosman A, Dubuisson J-B, Irion O, Dahoun S, Pelte M-F, Hovatta O, and Jaconi M. Derivation of a human embryonic stem cell line (hESC) from a single blastomere of an arrested four cell stage embryo. Swiss Med Wkly. 2008 Sep 20;138(37-38):540-50. (IF: 1.681) Cartier L, Laforge T, Feki A, Arnaudeau S, Dubois-Dauphin M, Krause KH. Pax6-induced alteration of cell fate: Shape changes, expression of neuronal alpha tubulin, post mitotic phenotype, and cell migration. J Neurobiol. 2006 Jan 19 (IF: 4.209) Feki A, Jefford CE, Krause KH, and Irminger-Finger I. BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNA-damage response kinase. Oncogene. 2005 May 26;24(23):3726-36. (IF: 7.216) Feki A, Jefford CE, Durand P, Harb J, Lukas H, Krause KH, Irminger-Finger I. BARD1 Expression During Spermatogenesis Is Associated with Apoptosis and Hormonally Regulated. Biol Reprod. 2004 Nov;71(5):1614-24. (IF: 3.469) Jefford CE, Feki A, Jean Harb, Krause KH, and Irminger-Finger I. Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity. Oncogene. 2004 Apr 29;23(20):3509-20. (IF: 7.216) Irminger-Finger I, Leung WC, Li J, Dubois-Dauphin M, Harb J, Feki A, Jefford CE, Soriano JV, Jaconi M, Montessano R, Krause KH. Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol Cell. 2001 Dec;8(6):1255-66. (IF: 16.811) Kulier R, Feki A, Hofmeyr GJ, Campana A. Surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev. 2001;(4):CD002900. (IF: 5.653) Reviews published or accepted in peer reviewed journals Bergström R, Ström S, Holm F, Feki A, Hovatta O. Xeno-free culture of human pluripotent stem cells. Methods Mol Biol. 2011;767:125-36. Mitsiadis TA, Feki A, Papaccio G, Catón J. Stem cells, niches and Notch signaling during dental pulp regeneration. Adv Dent Res. 2011 Jul;23(3):275-9. (IF: 3.458) Na J, Plews J, Li J, Wongtrakoongate P, Tuuri T, Feki A, Andrews PW, Unger C. Molecular mechanisms of pluripotency and reprogramming. Stem Cell Res Ther. 2010 Oct 25;1(4):33. Preynat-Seauve O, Burkhard PR, Villard J, Zingg W, Ginovart N, Feki A, Dubois-Dauphin M, Hurst S, Mauron A, Jaconi M, Krause KH. Pluripotent stem cells as new drugs? The example of Parkinson's disease. Int J Pharm. 2009 Nov 3;381(2):113-21. (IF: 3.061) Feki A, Berardi P, Bellingan G, Major A, Krause KH, Petignat P, Zehra R, Pervaiz S, and Irminger-Finger I. Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Crit Rev Oncol Hematol. 2009 Oct;72(1):1-9. (IF: 4.632) Feki A, Hovatta O, Jaconi M. Derivation of human embryonic stem cell lines from single cells of four cell stage embryos – be aware of the risks. Hum Reprod. 2008 Dec;23(12):2874. (IF: 3.543) Lei T, Jacob S, Agil-Zaraa I, Dubuisson JB, Irion O, Jaconi M and, Feki A. Human embryonic stem cells: Challenges and limitations toward their clinical use. Cell Res. 2007 Aug;17(8):682-8. (IF: 8.151) Feki A, Faltin DL, Dubuisson J-B, Jacob S, Irion O. Sphincter incontinence: Is regenerative medicine the best alternative to restore urinary or anal sphincter function? Int J Biochem Cell Biol. 2006 Nov 7 (IF:4.804) X lu, A Feki. Phenotipic Features with P53 Alterations Related to HPV and Prognostic Evaluation in Cervical Cancer. Int J Gynecol Cancer. 2006 Mar-Apr; 16(2):708-17. (IF: 1.932) Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Critical reviews in Oncology / Hematology. 2004 Nov;52(2):103-16. (IF: 4.632) Editorials published or accepted non peer reviewed journals Feki A, Fraisse T, Irion O, Dubuisson JB, Hovatta O. Preservation of women fertility facing potential premature ovarian failure. Rev Med Suisse. 2008 Oct 22;4(176):2264-6, 2268. D de Ziegler, N Vulliemoz, A Feki, V Ibecheole, P Ventura. Reproductive endocrinology and infertility in the light of 20 years of IVF experience. Rev Med Suisse. 2006 Feb 15; 2(53):438-40, 442. M Jaconi and A Feki. La nouvelle loi sur les cellules souches embryonnaires: un an après. Swiss Medical Forum. 2005; 5:1247-8. Xeno-Free Culture of Human Pluripotent Stem Cells. Rosita Bergström, Susanne Ström, Frida Holm, Anis Feki, and Outi Hovatta. Human Pluripotent Stem Cells. Methods and Protocols. Series: Methods in Molecular Biology, Vol. 767. Schwartz, Philip H.; Wesselschmidt, Robin (Eds.). 1st Edition., 2011, 425 p. 92. ISBN: 978-1-61779-200-7 Editorials submitted in peer reviewed journals Amiq Gazdhar, Iwona Grad, Mathias Gugger, Anis Feki, Thomas Geiser. iPS cells attenuate bleomycin induced lung injury in the rat lung. Submitted C. Pirard, A. Feki, J. Donnez, and E. Loumaye. GnRH agonist – New approach to the luteal phase: Rationale and clinical data on patient convenience. Submitted C. Pirard, A. Feki, J. Donnez, and E. Loumaye. A patient-friendly ART treatment using GnRH agonist as luteal phase support improved implantation: a prospective, randomized, comparative study. Submitted Hibaoui Y, Grad I, Vianin S, Bosman A, Borel C, Jaconi M, Antonarakis SE, Feki A. Ectoderm defect in iPS cell derived from fibroblasts of Monozygotic twins discordant for trisomy 21. Abstracts presented at international meetings Fekih A, Farah N, Chardonnens D, Urner F, De Ziegler D, Bianchi PG, Mock P, Campana A & Lucas H. Failed oocyte maturation in vitro. Journal of Reproduction and Fertility. 2000. Fekih A, Major A, Lüdicke F, Campana A, Irminger-Finger I: Molecular characterization of apoptotic pathway induced by PDT. EOS/SPIE European Biomedical Optics Weeks – EbiOS . 2000 A. Feki, Frank Lüdicke, Jian Li, Karl-Heinz Krause, Attila Major, Irmgard Irminger-Finger. Analysis of tumor suppressor function of BARD1 (BRCA1 associated Ring domain protein) in a rat ovarian cancer model. Proc. Amer. Assoc. Can. Res. 2001. 42,420. A. Feki, A. Major, F. Lüdicke, C. E. Jefford, A. Campana, and I. Irminger. Molecular characterization of apoptotic pathway induced by PDT: implication of tumor suppressor genes prospective markers. Cancer detection and prevention.2001. 24: S68. A. Feki, C. E. Jefford, M. Dubois-Dauphin, I. Irminger. Mechanism of apoptotic signaling by tumor suppressor BARD1. International J. of Mol. Medicine.2001. 8: 432. A. Feki, C.E. Jefford, J. Harb, M. Dunois-Dauphin, I. Irminger-Finger. The role of tumor suppressor BARD1 in cell death and life. Proc. Amer. Assoc. Can. Res. 2002. 43: 988. I. Irminger-Finger, A. Meisser, M. Hardy Sow, A. Feki, and Paul Bischof. Immunolocalization of BARD1 (BRCA1 Associated Ring Domain Protein 1) in early pregnancy trophoblast. Placenta. 2003. 24: A.26 A. Feki, C-E. Jefford, L. Cartier, A. Major, K-H. Krause and I. Irminger. Implication of BARD1 in tumor suppression and response to therapy: monitoring of tumor growth and regression by photomedicine and GFP-tagging. The Pezcoller Foundation Journal. 2003. 20:29 Elbarbary TM, Lucas H, Urner F, De Vantery C, F Pelte, Feki A, De Agostini A, and Chardonnens D. Spontaneous pregnancy after ovarian tissue cryopreservation by vitrification and intra-uterine transplantation. Reproduction. 2003. 30:82 Jefford CE, A. Feki, K-H. Krause, and I. Irminger. Role of tumor suppressor BARD1 in control of cell proliferation in development and malignant transformation. 8th Congress on Advances in Oncology & 6th International Symposium on Molecular Medicine. Greece, 2003. A. Feki, C-E. Jefford, L. Cartier, K-H. Krause and I. Irminger-Finger. Role of tumor suppressor BARD1 and malignant transformation. Cell and Molecular Biology of Cancer Meeting, Lausanne. January 2003 Feki A, Jefford CE, Durand P, Lucas H, Chardonnens D, Krause KH, and Irminger I. The role of a tumor suppressor gene BARD1 and its spliced variant in spermatogenesis. Reproduction. 2003. 30: 34 A. Feki, C-E. Jefford and I. Irminger. Role of tumor suppressor BARD1 in development and malignant transformation; implications for therapeutic interventions. New Insight in Molecular Diagnosis and Therapy. Paris, January 2004. D. de Ziegler, R. Uras, N. Vuillemoz, A. Feki, M. Yaron, V. Ibecheole. Endometriosis and IVF: to perform surgery or not? European meeting in reproduction medicine. Turkey 2005. S Ryser, A Feki, Ph Durand, Ph Tacchini, I Irminger-Finger. Identification of stem cell markers and potent testis-tumoral markers by expression profiling in male germinal stem cell. ELSO meeting, Dresden, Germany 2005. Jian-Yu Wu, Anis Feki, Charles Edward Efford and Irmgard Irminger-Finger. Role of tumor suppressor BARD1 in malignant transformation: Implications for therapeutic interventions. Proc Amer Assoc Cancer Res, Volume 46, 2005 Stephan Ryser, Anis Feki, Philippe Durand, Philippe Tacchini and Irmgard Irminger-Finger. Identification of stem cell markers and potent testis-tumoral markers by expression profiling in male germinal stem cell. Proc Amer Assoc Cancer Res, Volume 46, 2005 Feki A. Derivation of human embryonic stem cell line from single blastomere of an arrested four-cell stage embryo. MEFS 2008 Feki A. Challenges toward the use of human embryonic stem cells and induced pluripotent stem cells in regenerative medicine. MEFS 2008 Christelle Rochon, Valentina Castiglioni, Alessia Delli Carri, Luciano Conti, Caterina Mariotti, Stefano DiDonato, Marisa Jaconi, Outi Hovatta, Anis Feki, Elena Cattaneo. GENERATION OF iPS CELLS FOR MECHANISTICS STUDIES IN HUNTINGTON'S DISEASE. IV Meeting on the MOLECULAR MECHANISMS OF NEURODEGENERATION. May 8-10, 2009. Milano, Italy Audrey Letourneau, Stephen B. Montgomery, David Gonzalez, Daniel Robyr, Christelle Borel, Eugenia Migliavacca, Youssef Hibaoui, Laurent Farinelli, Maryline Gagnebin, Emilie Falconnet, Samuel Deutsch, Sophie Dahoun-Hadorn, Jean-Louis Blouin, Anis Feki, Roderic Guigo, Emmanouil T. Dermitzakis, Stylianos E. Antonarakis. Trisomy 21: a disease of chromatin architecture? The American Society of Human Genetics annual meeting 2011. Yaron M, Beck-Popovic M, Girardin C, Phan-Hug F, Wunder D, Primi MP, Feki A, Ibecheole V, Simon JP, Schwitzgebel V, Turello R, Bellavia M, Ambrosetti A, Gumy-Pause F. Fertility preservation in female pediatric cancer patients, a multidisciplinary approach. Société suisse de pédiatrie + Société suisse de chirurgie pédiatrique, Assemblée annuelle commune. Montreux, septembre 2011. Swiss Med Wkly, vol. 141 (2011), Suppl. No 187, p. 41S Posters presented at international meetings Fekih A, Major A, Lüdicke F, Campana A, Irminger-Finger I: Molecular characterization of apoptotic pathway induced by PDT. EOS/SPIE European Biomedical Optics Weeks – EbiOS . Amsterdam. 2000 Fekih A, Farah N, Chardonnens D, Urner F, De Ziegler D, Bianchi PG, Mock P, Campana A & Lucas H. Failed oocyte maturation in vitro. Meeting of the International Society of Fertility and Sterility. Edinburgh. 2000. A. Feki, A. Major, F. Lüdicke, C. E. Jefford, A. Campana, and I. Irminger. Molecular characterization of apoptotic pathway induced by PDT: implication of tumor suppressor genes prospective markers. Cancer detection and prevention Meeting, Geneva. 2001. Anis Feki, Frank Lüdicke, Jian Li, Karl-Heinz Krause, Attila Major, Irmgard Irminger-Finger. Analysis of tumor suppressor function of BARD1 (BRCA1 associated Ring domain protein) in a rat ovarian cancer model. 92nd Annual meeting of the AACR, New Orleans. 2001. C. E. Jefford, A. Feki, K-H. Krause and I. Irminger-Finger. Structure function studies on BARD1. 3rd Breakthrough Conference on the functions of BRCA1 and 2. Cambridge. 2001. C. E. Jefford, A. Feki, K-H. Krause and I. Irminger-Finger. BRCA1-associated protein BARD1 responds to stress by mediating p53-dependent apoptosis. Functional Genomics of Aging, Sevilla. 2002 A. Feki, C.E. Jefford, J. Harb, M. Dunois-Dauphin, I. Irminger-Finger. The role of tumor suppressor BARD1 in cell death and life. 93rd Annual meeting of the AACR, San Francisco. 2002. Elbarbary TM, Lucas H, Urner F, De Vantery C, F Pelte, Feki A, De Agostini A, and Chardonnens D. Spontaneous pregnancy after ovarian tissue cryopreservation by vitrification and intra-uterine transplantation. 3rd Joint meeting of the British Andrology Society, the British Fertility Society and the Society for Reproduction and fertility. Aberdeen 2003 Jefford CE, A. Feki, K-H. Krause, and I. Irminger. Role of tumor suppressor BARD1 in control of cell proliferation in development and malignant transformation. 8th Congress on Advances in Oncology & 6th International Symposium on Molecular Medicine. Greece, 2003. A. Feki, C-E. Jefford, and I. Irminger. Role of tumor suppressor BARD1 in development and malignant transformation; implications for therapeutic interventions. New Insight in Molecular Diagnosis and Therapy. Paris, January 2004. Christelle Rochon, Valentina Castiglioni, Alessia Delli Carri, Luciano Conti, Caterina Mariotti, Stefano DiDonato, Marisa Jaconi, Outi Hovatta, Anis Feki, Elena Cattaneo. GENERATION OF iPS CELLS FOR MECHANISTICS STUDIES IN HUNTINGTON'S DISEASE. IV Meeting on the MOLECULAR MECHANISMS OF NEURODEGENERATION. May 8-10, 2009. Milano, Italy Unger Christian, Plews Jordan, Na Jie, Feki Anis, Andrews Peter W. RELATIVE QUANTIFICATION OF TRANSCRIPTION FACTORS DURING THE PRODUCTION AND DIFFERENTIATION OF PLURIPOTENT STEM CELLS. ISSCR, Barcelona 2009. Y Hibaoui, I Grad, MR Sailani, A Letourneau, S Dahoun, MF Pelte, F Béna, SE Antonarakis, A Feki. Modelling neurogenesis impairment in Down syndrome disease using induced pluripotent stem cells derived from human monozygotic twins discordant for trisomy 21. Cell Symposia. Stem Cell Programming & Reprogramming. Lisbon, Portugal. December 8–10 2011, Abstracts presented at national meetings A. Feki, C-E. Jefford, A. Major, K-H. Krause, and I. Irminger. Cancer cell killing through proapoptotic tumor suppressor function of BARD1 in rat ovarian cancer model. USGEB. Fribourg, 2004. C-E. Jefford, A. Feki, S. Gargos, I. Bondarev, F. Calabria, S. Chang, I. Irminger-Finger. In vitro repression of BARD1 allows cells with critically short telomeres to pass M1 crisis. USGEB 2004 Feki A, Faltin D, Vlastos AT, Vlastos G, Irion O, Irminger-Finger I. Role of Tumor Suppressor BARD1 in Malignant Transformation; Implication for Therapeutic Interventions. Gynäkol Geburtshilfliche Rundsch 2005;45:175-76. Irminger-Finger I, Vlastos AT, Vlastos G, Feki A. P53 as a Prognostic Factor in Primary Breast and Ovarian Tumors: Analysis of Published Clinical Data. Gynäkol Geburtshilfliche Rundsch 2005;45:191. T. Elbarbary, F. Urner , D. Chardonnens, A Feki, H.Lucas. Ovarian tissue cryopreservation. 6th interactive day between Geneva and Lausanne medicine Faculties. Changin. 2002. A. Feki, C-E. Jefford, L. Cartier, K-H. Krause and I. Irminger-Finger. Role of tumor suppressor BARD1 and malignant transformation. Cell and Molecular Biology of Cancer Meeting, Lausanne. January 2003 A. Feki, C-E. Jefford, A. Major, K-H. Krause and I. Irminger. Cancer cell killing through proapoptotic tumor suppressor function of BARD1 in rat ovarian cancer model. USGEB. Fribourg, 2004. C-E. Jefford, A. Feki, S. Gargos, I. Bondarev, F. Calabria, S. Chang, I. Irminger-Finger. In vitro repression of BARD1 allows cells with critically short telomeres to pass M1 crisis. USGEB 2004. I Irminger Finger, A-T. Vlastos, G. Vlastos, A. Feki. P53 as a prognostic factor in primary breast and ovarian tumorsa: Analysis of published clinical data. SGGO meeting. Lugano 2005 Jungo Nançoz C, Dällenbach P, Vlastos G, Monnier S, Feki A, Dubuisson JB. From Surgical Pregnancy Termination to Uterine Perforation. SSGO meeting. Interlaken 2010 EOS/SPIE European Biomedical Optics Weeks – EbiOS. Molecular characterization of apoptotic pathway induced by PDT. Amsterdam. 2000 Cancer, Apoptosis and Aging workshop. The role of BARD1 in spermatogenesis. Geneva. 2002. XIXe Congrès de la Société d’Andrologie de Langue Française. BARD1 and testicular apoptosis. SALF 2002, 12-14 December, Geneva. Feki A, Jefford CE, Durand P, Lucas H, Chardonnens D, Krause KH, and Irminger I. The role of a tumor suppressor gene BARD1 and its spliced variant in spermatogenesis. Aberdeen. 2003. Presentation selected for the best young scientist. Feki A, D. Faltin, A-T. Vlastos, G. Vlastos, O. Irion, I. Irminger Finger. The role of BARD1 in malignant transformation; implication for therapeutic interventions. SGGO meeting. Lugano 2005 Feki A. The potential role of embryonic stem cells in regenerative medicine. Anti-Aging Medicine World Congress 2007, Monaco March 22-23-24 Feki A, Embryonic stem cell research: Quo vadis. Forum medical de la faculté de medicine de Sfax 2008, Tunisia April 17-18 Feki A. Derivation of human embryonic stem cell line from single blastomere of an arrested four-cell stage embryo. MEFS 2008 Feki A. Challenges toward the use of human embryonic stem cells and induced pluripotent stem cells in regenerative medicine. MEFS 2008 Feki A. PROMISES AND CHALLENGES TOWARDS THE CLINICAL USE OF PLURIPOTENT STEM CELLS. 15th World congress on IVF and IVM. Geneva, Switzerland, 19-22 April 2009. Feki A. Derivation methods and characterisation of hESC. 6th International Stem Cell School in Regenerative Medicine 2009. Odense, Denmark, 14-16 June, 2009. Feki A. Potential and drawbacks of pluripotent stem cells toward their clinical use. 6th International Stem Cell School in Regenerative Medicine 2009. Odense, Denmark, 14-16 June, 2009. Feki A. In vitro reprogramming of fibroblasts into pluripotent E-cell like state: epigenetic remodeling and tissue contribution. ESHRE annual meeting. Amsterdam, 28-1 july 2009. Feki A. Stem cells: State of the art. Meeting Internatzionale Ostetrico Neonatologico. September 16-18. Cuneo, Italy Feki A. After reprogramming: cloning is still fiction? 2nd Congress of Society of Reproductive Medicine. 1 – 4 October, 2009. Gloria Golf Resort, Antalya, Turkey Feki A. Pluripotent stem cells and reproductive medicine. Advances in REI & ART meeting. McGill. Montreal 2009. Canada Feki A. Monnier S, Dubuisson JB, Vlastos G. Stem cells and breast cancer: dream or reality? Manosmed course. Geneva 2010. Feki A. Dubuisson JB. Germ cells derived pluripotent stem cells: is it a fiction? The 20th STGO, 4th FGOM, and the 11th FEMGO joint meeting. 7 to 9th October 2010. Tunis. Tunisia Feki A. Cryo-préservation and transplantation of ovarian tissue. 29ème Congrès National de la SRMGO. 4 - 5 Février 2011 Hôtel Sheraton. Casablanca. Marocco Feki A. Stem cells and reproduction medicine. 29ème Congrès National de la SRMGO. 4 - 5 Février 2011 Hôtel Sheraton. Casablanca. Marocco Feki A. Understanding the oncogenetic potential of pluripotent stem cells. CIPF Fridays. February 2011. Valencia. Spain Feki A. Cancer stem cells as a target for future therapies: Science or fiction? GYN2011. 9-11 Juin. Monaco. Feki A. Pluripotent stem cells and disease model. GYN2011. 9-11 Juin. Monaco. Feki A. A patient-friendly ART treatment using GnRH agonists as luteal phase support improved implantation. Third Congress of the Society of Reproductive Medicine. Antalya, October 5th and 9th, 2011 Feki A. Pluripotent stem cells and germ cell differentiation in vitro. Third Congress of the Society of Reproductive Medicine. Antalya, October 5th and 9th, 2011

Source: http://www.genico.it/upload/File/download/CV_Feki.pdf

Microsoft word - rosacea 1.doc

THE ENVIRON SOLUTION: written by Dr Des Fernandes ‘Rosacea is a chronic skin problem that is not well understood’ and characteristically affects people with pale skins, blue eyes and generally starts in middle age. People with darker skins also get rosacea, but the signs are less florid. It is always associated with redness of the skin, often with small papules (or lumps) which

Microsoft word - fru september 2013.doc

FMFUSDAF Food Regulatory Update September 2013 FDA Holds First Public Meeting on FSVP and Third Party AccreditationTutorials on GRAS Notices, Additive Petitions Now Available in Six VideoFDA Reveals Pilot Program Aimed to Accelerate the Detection of Hazards in FOOD REGULATORY UPDATE I. U.S. ACTIVITIES FDA Releases Data on Rice Samples Tested for Inorganic Arsenic On September 6

Copyright © 2010-2014 Drug Shortages pdf